|
|
TLRa |
|
Vaxjo ID |
291 |
|
Vaccine Adjuvant Name |
TLRa |
|
Adjuvant VO ID |
VO_0005656
|
|
Components |
Toll-like receptor agonists (TLRa) have been widely evaluated as adjuvants because they activate the innate immune system. Currently, licensed vaccines adjuvanted with TLRa include the TLR4 agonist monophosphoryl lipid, while additional TLRa are in clinical development. |
|
Function |
Toll-like receptor agonists (TLRa) have been widely evaluated as adjuvants because they activate the innate immune system. Currently, licensed Vaccine adjuvanted with TLRa include the TLR4 agonist monophosphoryl lipid, while additional TLRa are in clinical development. |
| References |
Lodaya et al., 2018: Lodaya RN, Brito LA, Wu TYH, Miller AT, Otten GR, Singh M, O'Hagan DT. Stable Nanoemulsions for the Delivery of Small Molecule Immune Potentiators. Journal of pharmaceutical sciences. 2018; 107(9); 2310-2314. [PubMed: 29883663].
|
|
